HomeCompareACOR vs ADC

ACOR vs ADC: Dividend Comparison 2026

ACOR yields 302.57% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $45.5K in total portfolio value· pulled ahead in Year 10
10 years
ACOR
ACOR
● Live price
302.57%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$133.5K
Annual income
$200.19
Full ACOR calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — ACOR vs ADC

📍 ADC pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACORADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACOR + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACOR pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACOR
Annual income on $10K today (after 15% tax)
$25,718.61/yr
After 10yr DRIP, annual income (after tax)
$170.16/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, ADC beats the other by $68,507.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACOR + ADC for your $10,000?

ACOR: 50%ADC: 50%
100% ADC50/50100% ACOR
Portfolio after 10yr
$156.2K
Annual income
$40,498.74/yr
Blended yield
25.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

ACOR
Analyst Ratings
5
Buy
11
Hold
3
Sell
Consensus: Hold
Altman Z
-32.7
Piotroski
3/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACOR buys
0
ADC buys
0
No recent congressional trades found for ACOR or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACORADC
Forward yield302.57%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%40.4%
Portfolio after 10y$133.5K$178.9K
Annual income after 10y$200.19$80,797.29
Total dividends collected$70.1K$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldBuy

Year-by-year: ACOR vs ADC ($10,000, DRIP)

YearACOR PortfolioACOR Income/yrADC PortfolioADC Income/yrGap
1$25,829$15,128.59$10,990$580.36+$14.8KACOR
2$45,896$18,259.36$12,301$860.26+$33.6KACOR
3$64,270$15,161.61$14,104$1,298.62+$50.2KACOR
4$78,690$9,921.27$16,691$2,008.16+$62.0KACOR
5$89,875$5,676.30$20,580$3,205.09+$69.3KACOR
6$99,196$3,029.49$26,754$5,330.02+$72.4KACOR
7$107,702$1,562.46$37,196$9,345.14+$70.5KACOR
8$116,034$792.73$56,244$17,523.09+$59.8KACOR
9$124,555$399.09$94,286$35,736.21+$30.3KACOR
10← crossover$133,474$200.19$178,949$80,797.29$45.5KADC

ACOR vs ADC: Complete Analysis 2026

ACORStock

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Full ACOR Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this ACOR vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACOR vs SCHDACOR vs JEPIACOR vs OACOR vs KOACOR vs MAINACOR vs NNNACOR vs EPRTACOR vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.